Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease
The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · e3002-e3010
DOI: 10.1210/clinem/dgae892 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.12.2024. Verfasst von Rongguang Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Graves Disease, Immunoglobulins, Thyroid-Stimulating, Receptors, Thyrotropin, Autoantibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Context
Thyroid-stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) are specific biomarkers for Graves disease (GD), but their clinical characteristics are not fully understood.
Objective
To clarify the clinical features and prognostic significance of TSI and TRAb in patients with GD.
Methods
We conducted a retrospective data analysis and a follow-up study. Medical records of patients newly diagnosed with GD were examined. TSI and TRAb correlations were assessed using Passing-Bablok regression and Bland-Altman plot. Patients were categorized into unresolved (Group A) and resolved (Group B) hyperthyroidism based on thyroid function after 1 month of therapy. The relationship between thyroid function and changes in TRAb and TSI was analyzed. Logistic regression identified relapse risk factors, including TSI levels at antithyroid drugs (ATDs) withdrawal in the follow-up study.
Results
Data from 957 patients (762 female and 195 male) revealed a strong correlation between TRAb and TSI (r = 0.873, P < .001). Compared to group B, group A showed minimal antibody decline (100% [interquartile range (IQR) 87.91%-115.1%] and 100% [IQR 85.03%-118.3%], respectively). Among 206 patients followed for over 12 months after ATD discontinuation, the relapse rate was 41.26%. Relapse was more frequent in patients with positive TSI (54.84% vs 35.42%, P < .05). Positive TSI levels at withdrawal, past history of GD, age, and mild thyroid-associated ophthalmopathy were independent relapse predictors.
Conclusion
TSI and TRAb are strongly correlated in GD, with slow antibody decline linked to unresolved hyperthyroidism. Discontinuing ATDs may be considered when both TSI and TRAb are negative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruij…
ORCID-Profile: Pu Xie, Qinglei Yin, Liyun Shen, Lei Ye, Yulin Zhou, Shu Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Peng, R., Xie, P., Jin, Z., Zhou, W., Wang, Y., Chen, X., Yin, Q., Shen, L., Meng, L., Ye, L., Zhou, Y., & Wang, S. (2025). Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. The Journal of Clinical Endocrinology & Metabolism, 110(9), e3002-e3010. https://doi.org/10.1210/clinem/dgae892
Vancouver
Peng R, Xie P, Jin Z, Zhou W, Wang Y, Chen X, et al. Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):e3002-e3010. doi:10.1210/clinem/dgae892
BibTeX
@article{Peng2025,
author = {Peng, Rongguang and Xie, Pu and Jin, Zhou and Zhou, Wenzhong and Wang, Yanqiu and Chen, Xinxin and Yin, Qinglei and Shen, Liyun and Meng, Lingyang and Ye, Lei and Zhou, Yulin and Wang, Shu},
title = {Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {9},
pages = {e3002--e3010},
doi = {10.1210/clinem/dgae892}
}
EUVIMED